Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "CD31" patented technology

Platelet endothelial cell adhesion molecule (PECAM-1) also known as cluster of differentiation 31 (CD31) is a protein that in humans is encoded by the PECAM1 gene found on chromosome 17. PECAM-1 plays a key role in removing aged neutrophils from the body.

Preparation method and application of a core-shell composite flexible biomaterial

PendingCN122297794ATissue repairCD31
This invention discloses a method for preparing and applying a shell-core composite flexible biomaterial. The flexible biomaterial consists of an outer PMMA electrospun layer, a middle PTFF or PE layer, and a core PEG hydrogel; both the PMMA electrospun layer and the middle layer are porous. This flexible material is soft and elastic, exhibiting good film-forming and osteogenic induction effects. Animal experiments have confirmed that, compared to traditional bone cement, the flexible composite bone cement-induced biofilm shows an increase in CD31-positive cells (representing angiogenesis) and M2 macrophages (representing tissue repair), exhibiting better film-forming properties. It is a promising composite biomaterial that can be widely applied in the treatment of soft tissue defects, bone defects, and bone infections, achieving better therapeutic effects.
Owner:XIANGYANG CENT HOSPITAL

Use of harmalan in the preparation of a medicament for promoting neovascularization after myocardial infarction

PendingCN122440625AAngiogenesis growth factorPharmaceutical drug
The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

An injectable embolic agent, its preparation method and application

PendingCN122075535AImprove stabilityachieve controlled releaseOrganic active ingredientsSurgical adhesivesTransarterial embolizationEmbolization Agent
This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Application of TGF-β / Smad signaling pathway in treatment of corneal neovascularization in corneal alkali burn

The application belongs to the field of biological medicine, and provides application of TGF-beta / Smad signal pathway in treatment of corneal neovascularization after corneal alkali burn. The application proves that by inhibiting the TGF-beta / Smad signal pathway, the alkali burn-induced corneal neovascularization can be significantly reduced, and the corneal pathological damage is improved, and the mechanism of action involves regulating M2 type macrophage polarization and inhibiting the process of cellular ferroptosis of corneal tissue. It is found that by using a specific inhibitor SB-431542, the expression of TGF-beta1 and p-Smad2 / 3 proteins can be effectively reduced, the angiogenic factors such as VEGFA and CD31 are reduced, the inflammatory factors such as IL-4 and IL-10 are down-regulated, the GSH level is restored, and the Fe 2+ and MDA contents are reduced. The application is suitable for developing a targeted therapeutic drug for pathological neovascularization after corneal alkali burn, and provides a theoretical basis.
Owner:JINCHENG HOSPITAL